INFICON

Overview

INFICON, founded in 2000 and headquartered in Switzerland, operates within the manufacturing sector, specifically focusing on test and measurement equipment. The company employs between 1,001 and 5,000 individuals and reported a revenue of approximately $829.9 million. INFICON's expertise is particularly evident in the pharmaceutical industry, where it addresses the challenges associated with freeze-drying processes. One of its key offerings is the Transpector® CPM 3, a compact process monitor that utilizes residual gas analysis (RGA) to optimize freeze-drying. This technology is crucial for monitoring the decomposition of thermally sensitive materials, ensuring the stability of drug and biological products during the freeze-drying cycle. By integrating RGA with advanced freeze-drying systems, INFICON provides solutions that enhance product shelf life and quality. The company’s published content reflects a commitment to advancing process analytical technologies that support the pharmaceutical sector's needs, particularly in maintaining the integrity of active pharmaceutical ingredients during critical manufacturing processes.

Industry